DE68910138T2 - Fumagillin als angiostatisches Mittel. - Google Patents
Fumagillin als angiostatisches Mittel.Info
- Publication number
- DE68910138T2 DE68910138T2 DE89100714T DE68910138T DE68910138T2 DE 68910138 T2 DE68910138 T2 DE 68910138T2 DE 89100714 T DE89100714 T DE 89100714T DE 68910138 T DE68910138 T DE 68910138T DE 68910138 T2 DE68910138 T2 DE 68910138T2
- Authority
- DE
- Germany
- Prior art keywords
- fumagillin
- angiostatic agent
- angiostatic
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 title 1
- 239000004037 angiogenesis inhibitor Substances 0.000 title 1
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 title 1
- 229960000936 fumagillin Drugs 0.000 title 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14540788A | 1988-01-19 | 1988-01-19 | |
US07/173,305 US5135919A (en) | 1988-01-19 | 1988-03-25 | Method and a pharmaceutical composition for the inhibition of angiogenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
DE68910138D1 DE68910138D1 (de) | 1993-12-02 |
DE68910138T2 true DE68910138T2 (de) | 1994-04-28 |
Family
ID=26842945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE89100714T Expired - Fee Related DE68910138T2 (de) | 1988-01-19 | 1989-01-17 | Fumagillin als angiostatisches Mittel. |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0325199B1 (de) |
JP (1) | JP2806454B2 (de) |
CA (1) | CA1333363C (de) |
DE (1) | DE68910138T2 (de) |
ES (1) | ES2059571T3 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637575A (en) * | 1988-01-19 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting restenosis |
US5760015A (en) * | 1988-01-19 | 1998-06-02 | The Trustees Of The University Of Pennsylvania | Cyclodextrin compounds and methods of making and use thereof |
US5183809A (en) * | 1990-02-15 | 1993-02-02 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
US5658894A (en) * | 1989-04-23 | 1997-08-19 | The Trustees Of The University Of Pennsylvania | Compositions for inhibiting restenosis |
KR0138530B1 (ko) * | 1988-09-01 | 1998-05-15 | 우메모또 요시마사 | 푸마길롤 유도체 |
DE68915900T2 (de) * | 1988-09-01 | 1994-11-24 | Takeda Chemical Industries Ltd | Angiogenese hemmendes Mittel. |
US5135920A (en) * | 1988-11-16 | 1992-08-04 | Takeda Chemical Industries, Ltd. | Angiostatic agents |
US5441944A (en) * | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US5290807A (en) * | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
US6017954A (en) * | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
EP0415294A3 (en) * | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
US5227372A (en) * | 1990-03-07 | 1993-07-13 | Children's Medical Center Corporation | Method for retaining ophthalmological agents in ocular tissues |
TW282399B (de) * | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
US5202352A (en) * | 1990-08-08 | 1993-04-13 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis-inhibiting substance |
ATE196426T1 (de) * | 1991-06-21 | 2000-10-15 | Takeda Chemical Industries Ltd | Zyklodextrin-zusammensetzung enthaltend fumagillol-derivate |
CA2119233A1 (en) * | 1991-09-18 | 1993-04-01 | Fumio Shimojo | Transocular pharmaceutical preparation |
US5446030A (en) * | 1991-09-19 | 1995-08-29 | Weisz; Paul B. | Prevention of hemolysis |
EP0612249A4 (en) * | 1991-11-11 | 1995-11-08 | Univ Pennsylvania | Methods of inhibiting restenosis. |
DE69330690T2 (de) * | 1992-01-30 | 2002-06-20 | Takeda Chemical Industries Ltd | Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe |
JPH06157344A (ja) * | 1992-02-07 | 1994-06-03 | Childrens Medical Center Corp:The | 血管新生阻害のための医薬製剤及び血管新生阻害方法 |
EP0582459B1 (de) | 1992-08-07 | 1998-01-07 | Takeda Chemical Industries, Ltd. | Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten |
DE69311278T2 (de) * | 1992-12-16 | 1997-10-30 | Takeda Chemical Industries Ltd | Stabile pharmazeutische Zubereitung mit Fumagillolderivaten |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US8143283B1 (en) | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
US5328930A (en) * | 1993-03-01 | 1994-07-12 | Emory University | Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin |
US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
JPH08511041A (ja) * | 1993-03-31 | 1996-11-19 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルバニア | 哺乳動物生組織の増殖に作用する方法、及びそのための化合物ならびに組成物 |
ATE198152T1 (de) * | 1994-09-30 | 2001-01-15 | Takeda Chemical Industries Ltd | Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe |
US6117455A (en) * | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
AU2438297A (en) * | 1996-05-09 | 1997-11-26 | Alcon Laboratories, Inc. | Combinations of angiostatic compounds |
CA2270887C (en) | 1996-11-05 | 2006-03-21 | The Children's Medical Center Corporation | Methods and compositions for inhibition of angiogenesis |
JP2001513559A (ja) | 1997-08-25 | 2001-09-04 | ブレム,ハロルド | 新脈管形成インヒビターを用いる癒着および過剰な瘢痕形成の予防 |
US6673828B1 (en) | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
US8609614B2 (en) | 1998-07-22 | 2013-12-17 | Vanderbilt University | GBS toxin receptor compositions and methods of use |
FR2811572B1 (fr) * | 2000-07-17 | 2003-04-18 | Adir | Utilisation de cyclodextrines polysulfatees pour le traitement de l'arthrose |
AU2002253795B2 (en) | 2000-11-30 | 2007-02-01 | The Children's Medical Center Corporation | Synthesis of 4-Amino-Thalidomide enantiomers |
WO2007013147A1 (ja) * | 2005-07-27 | 2007-02-01 | Inbiotex Inc. | 血管新生阻害剤及び血管退縮剤 |
EP3624850A1 (de) | 2017-05-18 | 2020-03-25 | Tesaro, Inc. | Kombinationstherapien zur behandlung von krebs |
JP2020536066A (ja) | 2017-09-30 | 2020-12-10 | テサロ, インコーポレイテッド | 癌を治療するための併用療法 |
MX2020003799A (es) | 2017-10-06 | 2020-11-06 | Tesaro Inc | Terapias de combinacion y usos de las mismas. |
US11406612B2 (en) | 2018-02-26 | 2022-08-09 | Rensselaer Polytechnic Institute | Method of treatment via intra-articular application of potassium |
-
1989
- 1989-01-17 JP JP1005968A patent/JP2806454B2/ja not_active Expired - Lifetime
- 1989-01-17 DE DE89100714T patent/DE68910138T2/de not_active Expired - Fee Related
- 1989-01-17 ES ES89100714T patent/ES2059571T3/es not_active Expired - Lifetime
- 1989-01-17 EP EP89100714A patent/EP0325199B1/de not_active Expired - Lifetime
- 1989-01-17 CA CA000588398A patent/CA1333363C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE68910138D1 (de) | 1993-12-02 |
CA1333363C (en) | 1994-12-06 |
EP0325199A3 (de) | 1991-05-08 |
EP0325199B1 (de) | 1993-10-27 |
JPH01279828A (ja) | 1989-11-10 |
ES2059571T3 (es) | 1994-11-16 |
EP0325199A2 (de) | 1989-07-26 |
JP2806454B2 (ja) | 1998-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE68910138D1 (de) | Fumagillin als angiostatisches Mittel. | |
DE3682091D1 (de) | Trichostatine a und c als antikrebsmittel. | |
DE69007507D1 (de) | Fungizides Mittel. | |
DE10299035I2 (de) | Trizole als schimmelhemmene Mittel. | |
DE68922366D1 (de) | Piperidinyl-Benzimidazole als Antihistaminica. | |
DE69000203T2 (de) | Drehstablager. | |
DE601698T1 (de) | Topisches Mittel enthaltend Tocopherol. | |
FI892377A (fi) | Ny polymerkomposition. | |
DE68914495T2 (de) | Antihypercholesterolemisches Mittel. | |
DE68907794D1 (de) | Positioniermittel. | |
NO890503L (no) | Vandig blekemiddel. | |
DE3585719D1 (de) | Oxindol-derivate als antiinflammatorische mittel. | |
DE69003121D1 (de) | Filmbildendes Mittel. | |
DE68915269T2 (de) | Polyvalentes entzündungshemmendes mittel. | |
DE3878774D1 (de) | Paraherquamid und dihydroparaherquamid als antiparasitaere mittel. | |
DE68912476T2 (de) | Substituierte Thienopyrane als blutdrucksenkendes Mittel. | |
ATE100094T1 (de) | Imidazolantiarrythmische mittel. | |
FI905506A0 (fi) | Viskoelastisk daempare. | |
ATE96316T1 (de) | Fumagillin als angiostatisches mittel. | |
DE69009706T2 (de) | Thrombolytische Mittel. | |
DE3761240D1 (de) | Antihypoxisches mittel. | |
DE69406293T2 (de) | Benzothiophen analoga als antivirale mittel | |
DE68912159D1 (de) | Dioxoquinazolinderivat enthaltendes Antihypertensivum. | |
DE68907244D1 (de) | Anti-arteriosklerotisches mittel. | |
ATE100454T1 (de) | Substituierte thienopyrane als blutdrucksenkendes mittel. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |